Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Francis P. Worden et al.|The Lancet Oncology|2021Cited by 257
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based ImmunotherapyYulian Khagi, Razelle Kurzrock, Assuntina G. Sacco et al.|Clinical Cancer Research|2017Cited by 202
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and NeckRobert L. Ferris, Ezra E.W. Cohen, James Kyle Bryan et al.|JAMA Oncology|2018Cited by 111
Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patientsAshleigh Porter, Ezra E.W. Cohen, Mandy Natsuhara et al.|Translational Cancer Research|2020Cited by 28
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinomaMichael J. Dennis, Kathryn A. Gold, Assuntina G. Sacco et al.|Oral Oncology|2022Cited by 21